Changes in Cancer Diagnostics and Impact on Clinical Decisions

The treatment paradigm in oncology is shifting rapidly. With the advent of targeted therapies, the importance of molecular diagnostics is rapidly growing. The role of the cancer pathologist is changing, and so is the oncologist’s reliance on molecular markers in their clinical decision-making. Shared decision-making is common.

MDoutlook delivers deep insight into the changes in clinical decision-making; by specialist, by tumor-type, by stage of disease, even by molecular sub-type. In the past six months, our clients have commissioned US and EU studies in lung cancer, melanoma, renal cell carcinoma, breast cancer, non-Hodgkin lymphoma, CLL and several other malignancies.

Focal point in all studies has been the role of diagnostics and impact on clinical decision-making; e.g. this recent study in NSCLC: MDoutlook US NSCLC_final_131120_20

Interested in similar insight customized to your specific needs? By accessing the largest validated global panel of 75,000+ cancer HCPs (including onco-paths), MDoutlook collects and analyzes ground-level information to answer your business critical questions.

Want to know more about our existing studies to quickly answer a question? Our team of medical analysts can data-mine and meta-analyze our existing research to provide a targeted answer to your questions.

Contact us through this form or give us a call at +1.404.496.4136. And you can also visit us at the upcoming ASCO meeting in booth 6038.